


1	Supplemental Appendix
2	
3	The role and prognostic value of growth differentiation factor 15 in patient of
4	heart failure with preserved ejection fraction: Insights from the PURSUIT-HFpEF
5	Registry
6	
7	• Supplemental Figure
8	• Supplemental Table
9	• Collaborators list
10	

1 **Supplemental Figure 1. Distribution of GDF15**

2
3



4
5
6
7
8
9

6 The distribution of GDF15 is shown using a histogram. In the histogram, the x-axis

7 shows GDF15 level, and the y-axis shows the number of patients. Abbreviations:

8 GDF15, growth differentiation factor 15.

1 **Supplemental Table 1. Comparison of background of patients included and those**
2 **not included for analysis of GDF15**

3

Characteristic	Patients included (N = 181)	Patients not included (N = 1050)	P value
Age (years)	81.0 [75.0, 85.0]	83.0 [77.0, 87.0]	<0.01
Male sex	86 (47.5)	465 (44.3)	0.47
Body mass index (kg/m ²)	21.5 [19.3, 24.3]	21.4 [18.9, 24.3]	0.71
NYHA ≥ II	116 (64.1)	658 (64.0)	>0.99
Clinical frailty scale ≥ 5	32 (17.7)	348 (33.2)	<0.01
Smoking history	75 (41.7)	385 (37.3)	0.30
Systolic blood pressure	126.0 [112.0, 136.0]	117.0 [105.0, 129.0]	<0.01
Heart rate	70.0 [60.0, 76.0]	70.0 [61.0, 80.0]	0.39
Past medical history			
Atrial fibrillation	70 (38.7)	561 (53.4)	<0.01
Coronary artery disease	35 (19.6)	177 (17.1)	0.48
Hypertension	162 (89.5)	877 (83.8)	0.07
Diabetes mellitus	67 (37.2)	336 (32.2)	0.22

Dyslipidemia	87 (48.3)	436 (41.8)	0.12
COPD	18 (10.1)	70 (7.0)	0.20
Dialysis	6 (3.3)	12 (1.1)	0.06

Medication at discharge

ACE-Is/ARBs	90 (49.7)	562 (53.9)	0.34
β blockers	128 (70.7)	541 (51.9)	<0.01
Diuretics	155 (85.6)	840 (80.5)	0.13
MRAs	70 (38.7)	415 (39.8)	0.84
SGLT2 inhibitors	18 (9.9)	63 (6.1)	0.07
Biguanides	7 (3.9)	31 (3.0)	0.67

Laboratory data

Albumin (g/dL)	3.3 [3.1, 3.6]	3.4 [3.1, 3.7]	0.27
Hemoglobin (g/dL)	11.6 [10.0, 13.1]	11.2 [10.1, 12.6]	0.39
Sodium (mEq/L)	140.0 [138.0, 141.0]	139.0 [137.0, 141.0]	0.27
eGFR (mL/min/1.73m ²)	43.9 [28.1, 58.4]	40.9 [29.5, 53.7]	0.51
Cholinesterase (U/L)	208.0 [172.0, 255.0]	207.0 [165.0, 254.0]	0.28
C-reactive protein (mg/dL)	0.6 [0.2, 1.6]	0.2 [0.1, 0.8]	<0.01
Hemoglobin A1c	6.0 [5.6, 6.5]	6.0 [5.6, 6.5]	0.70

LDL cholesterol	92.0 [73.0, 113.5]	91.0 [73.0, 109.0]	0.38
NT-proBNP (pg/mL)	1280.0 [529.2, 2995.0]	1058.5 [492.0, 2370.8]	0.17
Echo cardiography at discharge			
LVDd (mm)	46.4 [42.0, 51.2]	45.0 [41.0, 49.9]	0.04
LVEF (%)	61.0 [55.0, 65.0]	61.0 [55.1, 65.6]	0.60
LAVI (mL/m ²)	50.0 [37.0, 64.8]	51.0 [38.0, 67.0]	0.42
LVMI (g/m ²)	117.9 [98.9, 146.3]	99.5 [82.3, 119.6]	<0.01
TAPSE (mm)	17.4 [15.1, 20.4]	17.3 [14.6, 20.2]	0.57
Mean E/e'	12.7 [10.0, 17.2]	12.4 [9.7, 16.7]	0.48
TRPG (mmHg)	25.9 [20.4, 32.0]	27.0 [22.0, 33.0]	0.02
Nutritional status			
CONUT score	3.0 [2.0, 5.0]	3.0 [2.0, 5.0]	0.57
GNRI	91.2 [84.5, 98.3]	92.0 [84.5, 99.2]	0.67
PNI	40.6 [37.4, 44.4]	41.1 [37.2, 44.8]	0.36

1

2 This comparison summarizes the difference between patients included and those not

3 included. Data are shown as median [interquartile range] or number (percentage).

4 Abbreviations: GDF15, Growth differentiation factor 15; NYHA, New York Heart

1 Association; COPD, chronic obstructive pulmonary disease; ACE-Is,
2 angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers;
3 MRAs, mineralocorticoid receptor antagonists; SGLT2 inhibitors, sodium glucose
4 cotransporter2 inhibitors; eGFR, estimated glomerular filtration rate; LDL, low density
5 lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic peptide; LVDd, left
6 ventricular diastolic diameter; LVEF, left ventricular ejection fraction; LAVI, left atrial
7 volume index; LVMI, left ventricular mass index; TAPSE, tricuspid annular plane
8 systolic excursion; E, early diastolic velocity on transmitral doppler; e', early diastolic
9 velocity of the mitral valve annulus; TRPG, tricuspid regurgitation pressure gradient;
10 CONUT, controlling nutritional status; GNRI, geriatric nutritional risk index; PNI,
11 prognostic nutritional index.
12

Collaborators list

The OCVC-Heart Failure Investigators

Chair: Yasushi Sakata, Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita 565-0871, Japan.

Study manager: Yohei Sotomi (Chief), Daisaku Nakatani, Katsuki Okada, Tomoharu Dohi, Akihiro Sunaga, Hirota Kida, Taiki Sato, Yuki Matsuoka, and Daisuke Sakamoto; Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.

Collaborators: Masahiro Seo, Tetsuya Watanabe, and Takahisa Yamada, Osaka General Medical Center, Osaka, Japan; Takaharu Hayashi and Yoshiharu Higuchi, Osaka Police Hospital, Osaka, Japan; Masaharu Masuda, Mitsutoshi Asai, and Toshiaki Mano, Kansai Rosai Hospital, Amagasaki, Japan; Hisakazu Fuji, Kobe Ekisaikai Hospital, Kobe, Japan; Shunsuke Tamaki, Daisaku Masuda, Ryu Shutta, and Shizuya Yamashita, Rinku General Medical Center, Izumisano, Japan; Masami Sairyo and Yusuke Nakagawa, Kawanichi City Medical Center, Kawanishi, Japan; Haruhiko Abe, Yasunori Ueda, and Yasushi Matsumura, National Hospital Organization Osaka National Hospital, Osaka, Japan; Kunihiro Nagai, Ikeda Municipal Hospital, Ikeda, Japan; Masamichi Yano, Masami Nishino, and Jun Tanouchi, Osaka Rosai Hospital, Sakai, Japan; Yoh Arita and, Nobuyuki Ogasawara, Japan Community Health Care Organization Osaka Hospital, Osaka, Japan; Takamaru Ishizu, Minoru Ichikawa and Yuzuru Takano, Higashiosaka City Medical Center, Higashiosaka, Japan; Eisai Rin, Kawachi General Hospital, Higashiosaka, Japan; Yukinori Shinoda, Koichi Tachibana and Shiro Hoshida, Yao Municipal Hospital, Yao, Japan; Masahiro Izumi, Kinki Central Hospital, Itami, Japan; Hiroyoshi Yamamoto and Hiroyasu Kato, Japan Community Health Care Organization, Osaka Minato Central Hospital, Osaka, Japan; Kazuhiro Nakatani and Yuji Yasuga, Sumitomo Hospital, Osaka, Japan; Mayu Nishio and Keiji Hirooka, Saiseikai Senri Hospital, Suita, Japan; Takahiro Yoshimura, Kazunori Kashiwase and Shinji Hasegawa, National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan; Akihiro Tani, Kano General Hospital, Osaka, Japan; Yasushi Okumoto, Kinan Hospital, Tanabe, Japan; Yasunaka Makino, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Japan; Toshinari Onishi and Katsuomi Iwakura, Sakurabashi Watanabe Hospital, Osaka, Japan; Yoshiyuki Kijima, Japan Community Health Care Organization, Hoshigaoka Medical Center, Hirakata, Japan; Takashi Kitao, Minoh City Hospital, Minoh, Japan; Masashi Fujita, Osaka International Cancer Institute, Osaka, Japan; Koichiro Harada, Suita Municipal Hospital, Suita, Japan; Masahiro Kumada and Osamu Nakagawa, Toyonaka Municipal Hospital,

1 Toyonaka, Japan; Ryo Araki and Takayuki Yamada, Otemae Hospital, Osaka, Japan;
2 Akito Nakagawa and Yoshio Yasumura, Amagasaki Chuo Hospital, Amagasaki, Japan;
3 and Daisuke Sakamoto, Yuki Matsuoka, Taiki Sato, Akihiro Sunaga, Hirota Kida, Yohei
4 Sotomi, Tomoharu Dohi, Yasuhiro Akazawa, Kei Nakamoto, Katsuki Okada, Fusako Sera,
5 Hidetaka Kioka, Tomohito Ohtani, Toshihiro Takeda, Daisaku Nakatani, Shungo Hikoso,
6 and Yasushi Sakata, Osaka University Graduate School of Medicine, Suita, Japan.

7

8